Peptides are short chains of amino acids. Dozens of them are marketed for healing, fat loss, sleep, cognition and anti-ageing, usually as injections, and usually with a great deal of confidence. This page sets out what the human evidence actually supports, because that is harder to find than the marketing.
The evidence is mostly not in humans
The great majority of published peptide research is preclinical — cell culture and animal models. That work is real and often interesting, but it is the beginning of a research process rather than the end of one. Many compounds that perform well in rodents do nothing measurable in people, and the ones that do are the reason drug approval takes years.
Where human data exists for these compounds it is typically small, uncontrolled and short. A handful of participants, no placebo group, no blinding, and outcomes measured over weeks. Studies of that shape can generate a hypothesis. They cannot establish that something works.
That is not an argument that peptides do nothing. It is an argument that anyone telling you what a peptide will do for your condition is going beyond what the research currently supports.
Where they stand with the FDA
As of August 2026: none of these compounds is FDA-approved for any use. BPC-157, CJC-1295 and thymosin beta-4 (TB-500) were nominated for the FDA’s 503A Bulks List and are no longer in Category 2 — the nominations were withdrawn before evaluation was completed, and the FDA’s April 2026 listing places them in its withdrawn table. On 23 July 2026 the FDA’s Pharmacy Compounding Advisory Committee proposed that TB-500 not be added to the Bulks List at all.
This last point is widely misreported, and it is worth being precise about. Coming off Category 2 is not permission. For a bulk substance to be compounded under section 503A it generally needs a USP monograph, or to be a component of an FDA-approved drug, or to appear on the 503A Bulks List. These compounds meet none of those. Withdrawal from nomination means the question was never answered — not that it was answered favourably.
Why there is no dosing on this page
This page used to publish dosing ranges. It no longer does, deliberately. Dosing for an unapproved compound with no established human safety profile is not information a website should be supplying, and publishing it implies a confidence the evidence does not support. If you are considering peptide therapy, the dose belongs in a conversation with whoever is prescribing it and taking responsibility for the outcome.
What Venturis Clinic provides
Venturis Clinic does not provide peptide therapy. It is available through Alpha Men’s Clinic, a separate telehealth practice. Dr. Philipose retains a financial interest in Alpha Men’s Clinic.
If you want to think through whether peptide therapy is a reasonable thing to try, the companion page on what to ask before you start is the more useful read. If you are researching BPC-157, TB-500 or CJC-1295 specifically, those three have their own page.
This page is educational and is not medical advice. Regulatory status is current as of August 2026 and is subject to change. Reviewed by Alvin Philipose, DC, ICCP · Last reviewed August 2026.